Why Vertex Pharmaceuticals Stock Is Down Sharply - Barron's
1. VRTX's earnings missed expectations, adjusted earnings at $4.06 per share. 2. Revenue of $2.77 billion fell short of $2.85 billion expectations. 3. Stock dropped 13%, marking its worst day since October 2020. 4. Leerink Partners downgraded VRTX citing limited access to Journavx pain medication. 5. Only 45% of insured have broad access to Journavx without prior authorization.